JAMP Pharma Group signs a landmark partnership agreement

Canadian pharmaceutical company JAMP Pharma Group has signed an exclusive agreement with global speciality biopharmaceutical company Alvotech for the Canadian commercial rights to five biosimilars. The current market value of the branded sales for these five biosimilars is estimated to be exceeding $2 billion annually in Canada.  Read the Press Release